Demand for high-end capsule filling technologies, particularly those used for early clinical development projects, has increased in 2010 according to Capsugel.
Drug manufacturers do not pay enough attention to the colour of their drugs, according to researchers examining the importance of aesthetics in pharmaceutical over-the-counter (OTC) products.
Nose-to-brain delivery can become a reality, even for molecules with high molecular weights, but barriers relating to administration and adsorption remain, according to a panel at AAPS.
Outsourcing-Pharma reviews the latest developments in drug delivery with news from HepaLife Technologies and Jeiven, SurModics and Edge, as well as EDAP, Epitarget AS and INSERM.
Celanese has launched a new controlled-release EVA excipient and says developing enhanced formulations is key to a drugmaker’s competitive edge in today’s pharmaceutical market.
Alnylam Pharmaceuticals, Medtronic and CHDI Foundation are collaborating to advance RNAi delivered by an implantable infusion device for treating Huntingdon’s.
B. Braun is recalling lots of its injectable anticoagulant, Heparin, manufactured in 2008, after finding a sample used to manufacture Heparin Sodium USP active pharmaceutical ingredients (APIs) was contaminated.
Aoxing Pharma and Johnson Matthey team up to research, develop, manufacture and market active pharmaceutical ingredients (APIs) for narcotics and neurological drugs in China.
Drug industry demand for chemical intermediates and development projects has rebounded significantly in the last 12 months according to UK group Endeavour Specialty Chemicals.
Drug delivery and pharmaceutical coating technologies firm SurModics will cut jobs and reorganise operations in a bid to reverse falling revenues and tumbling profits.
SoluBest and Dr Reddy’s Laboratories are joining forces to develop a proprietary formulation of one of SoluBest’s pipeline compounds using its Solumer platform.
Novartis will use technology from Synthetics Genomics Vaccines to speed up the development of influenza vaccines for seasonal and pandemic flu outbreaks.
Novo Nordisk is investing $73m in the expansion of its manufacturing facility in Clayton, North Carolina, to make room for increased production capacity for the biopharma giant’s insulin delivery services.
Univar is now exclusively distributing Dow's Carbowax Sentry PEGs in Europe and the range is proving popular at CPhI 2010 with manufacturers facing restricted supply from other sources.
Galapagos’ acquisition, Argenta, has signed up to a $46m cancer drug discovery service deal with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.
RXi and EyeGate lift the lid on ocular delivery of RNAi therapeutics for retinal disorders as the two firm’s team up to provide a unique needle-free solution.
Cost-effective, large-scale production of oncology drug Taxol (paclitaxel) intermediates could eventually be achieved using engineered Escherichia coli.
RXi Pharmaceuticals and EyeGate Pharma will unite to develop non-invasive, needle-free ocular delivery of RNAi therapeutics using the EyeGate II system for the treatment of retinal disorders.
Sheffield Bio-Science takes on responsibility for global sales, distribution and development of Girus Life Sciences’ chemically defined Regocel supplements.
Apricus Bio’s NexACT drug delivery technology has qualified as an anti-microbial preservative, according to results from a US Pharmacopeia Preservative Efficacy Test (USP PET).
Reengineering erythropoietin (EPO) as an immunoglobulin G (IgG) fusion protein enables penetration of the blood-brain barrier (BBB) in mice, according to researchers.
IDT Biologika unveils plans to expand viral vaccine contract manufacturing operations and says global capacity failing to keep pace with resurgence in drug industry demand.
in-pharmatechnologist presents a roundup of the latest drug sector manufacturing expansions with Sanofi Aventis, Takeda, Cerbios and Alliance Medical all adding capacity.
Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.
